Project Grant R01EY035307

Award Date 7/1/24
Completion Date 6/29/29
Dollars Obligated $459K
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
This $665,243 Project Grant, awarded by the National Eye Institute under the Vision Research program (CFDA 93.867), supports research at The Ohio State University to investigate the use of polarized myeloid cells for enhancing retinal ganglion cell (RGC) survival and optic nerve regeneration. The research aims to elucidate the factors secreted by interleukin-4 and granulocyte-colony stimulating factor polarized bone marrow neutrophils that promote neuroprotective and pro-regenerative effects,...
This Project Grant award, ID R01EY036880, was provided by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) to support research on the role of optic nerve head astrocytes in the development of glaucomatous optic nerve damage. The total funding amount is $387,428, awarded from March 1, 2025 through February 28, 2030. The research aims to investigate how transient biomechanical strains on the optic nerve head prime astrocytes to develop greater dysfunction, including...
This Project Grant award, provided by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), supports research on how neuronal activity and neurotransmitters, specifically glutamate, influence retinal angiogenesis and blood-retina barrier (BRB) maturation. The $248,999 award to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University will fund a 3-year study to investigate the mechanisms by which synaptic glutamate release regulates deep...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to evaluate the regenerative potential of human retinal ganglion cells (RGCs) and the regrowth of the optic nerve. The $147,486 award to The Johns Hopkins University aims to identify intrinsic factors that regulate RGC survival, axonal outgrowth, and functional recovery in a regenerative animal model, the zebrafish. The research will also test how modulation of these...
This Project Grant award, valued at $132,597.00 and provided by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), supports research aimed at improving retinal ganglion cell (RGC) replacement therapies for glaucoma. The research project, conducted by The Schepens Eye Research Institute, Inc., a non-profit organization in Boston, Massachusetts, focuses on investigating the role of neural activity in regulating the integration of transplanted RGCs within the host...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides $1,298,882 to the University of Oklahoma Health Sciences Center to investigate the role of extracellular microRNAs (miRNAs) in mediating communication between retinal pigment epithelium (RPE) and retinal microglia cells. The primary goals are to study the transfer of miRNAs between these cell types and evaluate the use of engineered RPE-derived extracellular vesicles (EVs) as...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), will provide $1,083,078.00 to the University of California, Irvine (UC Irvine) over the period of September 30, 2024 to June 30, 2028. The project aims to examine the role of monocytes and neutrophils in fungal keratitis, a leading cause of corneal blindness and vision loss. Key objectives include investigating neutrophil activation and the effect of monocyte depletion on...
This $499,116 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to develop stem cell-derived neuronal relays to regenerate the optic nerve and restore vision. The key objectives are to: 1) measure the functional recovery from long-term optic nerve grafted neural stem cells in the injured visual system, 2) investigate the role of guidance cues on directing neuronal relay axons through the optic chiasm, and 3) target the...
This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $414,711 to Albert Einstein College of Medicine to establish and utilize a microphysiological system for elucidating the mechanisms underlying early optic disc and stalk development, retinal ganglion cell (RGC) differentiation, axon growth, and pathfinding in human development and the pathogenesis of blinding retinal diseases. The award aims to gain a deeper understanding of RGC differentiation and...

ARGINASE POSITIVE MONOCYTE MEDIATED RGC NEUROPROTECTION AFTER TRAUMATIC OPTIC NEUROPATHY - PROJECT SUMMARY: ACUTE RETINAL GANGLION CELL (RGC) AND OPTIC NERVE INJURY DUE TO TRAUMA, AUTOIMMUNE INFLAMMATION, AND ISCHEMIA REPERFUSION RESULTS IN PERMANENT DISABILITY DUE TO EVENTUAL NEURONAL DEATH. TRADITIONALLY, INFLAMMATION AFTER ACUTE NEURONAL INJURY HAS BEEN CONSIDERED A MAJOR DRIVER OF SECONDARY DAMAGE, LEADING TO NEURONAL LOSS. THE INNATE IMMUNE RESPONSE OF INFILTRATING NEUTROPHILS AND MONOCYTES (MYELOID CELLS) AFTER NEURONAL INJURY RESULTS IN PRODUCTION OF MATRIX METALLOPROTEASES, PROINFLAMMATORY CYTOKINES, AND REACTIVE OXYGEN SPECIES THAT ARE DIRECTLY NEUROTOXIC, AND CONTRIBUTE GLIAL CELL MODULATION THAT PREVENT NEUROLOGICAL RECOVERY. HOWEVER, ANIMAL MODEL STUDIES HAVE DEMONSTRATED THAT CERTAIN IMMUNE CELL SUBSETS CAN HAVE NEUROPROTECTIVE AND REPARATIVE EFFECTS INCLUDING IN THE EYE. WE HAVE IDENTIFIED THAT THIS IMMUNE MEDIATED REGENERATION AFTER OPTIC NERVE CRUSH IS INITIATED BY A NOVEL IMMATURE ALTERNATIVELY ACTIVATED NEUTROPHIL CHARACTERIZED AS LY6GLOW CD14+ CD101-. THESE ALTERNATIVELY ACTIVATED NEUTROPHILS RECRUIT ARGINASE+ (ARG+) MONOCYTES THAT STAY AT THE SITE OF INJURY AND CONTINUE TO STIMULATE AXON REGENERATION. ADDITIONALLY, ALTERNATIVELY ACTIVATED NEUTROPHILS MODULATE MICROGLIA THAT LIKELY CONTRIBUTE TO THE NEURO-REPARATIVE ENVIRONMENT AFTER RGC INJURY. THE PRESENCE OF ARG+ MONOCYTES IN THE CENTRAL NERVOUS SYSTEM AFTER INJURY HAS BEEN ASSOCIATED WITH INFLAMMATION RESOLUTION AND NEUROREPAIR, HOWEVER THE MECHANISM IN WHICH ARG+ MONOCYTES DO THIS IS NOT KNOWN. IN ADDITION TO UNDERSTANDING THE BENEFICIAL EFFECTS OF ALTERNATIVELY ACTIVATED NEUTROPHILS ON RECRUITED MONOCYTES AND MICROGLIA, WE HAVE ALSO IDENTIFIED A HUMAN MONOCYTE POPULATION THAT SHOWS NEUROPROTECTIVE EFFECTS AND STIMULATES AXON REGENERATION AFTER ONC. THE OVERALL GOALS OF THIS WORK ARE BASED ON THE HYPOTHESIS THAT MONOCYTES CAN BE POLARIZED IN SITU TOWARDS THE UNIQUE NEUROREGENERATIVE PHENOTYPE TO IMPROVE NEURONAL RECOVERY AFTER ONC. THIS HYPOTHESIS WILL BE INTERROGATED IN THREE AIMS. IN AIM 1 WE WILL DETERMINE THE INTERACTIONS BETWEEN NEUTROPHILS AND MONOCYTES THAT RESULT IN MONOCYTE POLARIZATION TOWARDS AN ARG+ REPARATIVE PHENOTYPE. IN AIM 2, WE WILL FOCUS ON THE ROLE OF RETINAL MICROGLIA IN CONTRIBUTING TO MODULATION OF THE OCULAR INFLAMMATORY ENVIRONMENT AND POLARIZATION OF IMMUNE CELLS TOWARDS A NEURO-REPARATIVE PHENOTYPE. AIM 3 WILL DETERMINE THE TRANSLATIONAL CAPACITY OF THESE MECHANISTIC MOUSE EXPERIMENTS BY EXPLORING THE NEUROREGENERATIVE CAPACITY OF POLARIZING HUMAN MONOCYTES TO STIMULATE AXON REGENERATION AFTER ONC. THE OUTCOMES OF THESE STUDIES WILL BE TO UNDERSTAND THE UNDERLYING CYTOKINE, GROWTH FACTOR AND METABOLIC SIGNALS THAT INFLUENCE MONOCYTES TO TAKE ON A NEURO-REPARATIVE ROLE AFTER OPTIC NERVE INJURY. TO DATE, THE ROLE OF ARG+ MYELOID CELLS ON NEUROPROTECTION HAS BEEN CORRELATIVE. THIS WORK WILL HELP US GAIN A MECHANISTIC UNDERSTANDING OF THE FACTORS RESPONSIBLE FOR DRIVING MYELOID CELLS TOWARDS THE NEURO-REGENERATIVE PHENOTYPE AND COULD LEAD TO IMMUNE BASED THERAPIES TO DRIVE NEURON RECOVERY AFTER ACUTE INJURY.

Posted 6/7/24, 12:00 AM